Advanced Therapeutics最新文献_第10页

Ferric-Tannic Nanoparticles Inhibit Early-Stage Hepatocarcinogenesis by Activating Tumor Immune Responses in Rats 铁单宁纳米颗粒通过激活肿瘤免疫反应抑制大鼠早期肝癌的发生

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-30 DOI: 10.1002/adtp.202400348

Jannarong Intakhad, Arpamas Vachiraarunwong, Rawiwan Wongpoomchai, Chalermchai Pilapong

引用次数: 0

The Dawning Era of Anticancer Nanomedicines: From First Principles to Application of Silk Nanoparticles 抗癌纳米药物的黎明时代：从最初的原理到纳米丝的应用

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-30 DOI: 10.1002/adtp.202400130

Saphia A. L. Matthew, F. Philipp Seib

{"title":"The Dawning Era of Anticancer Nanomedicines: From First Principles to Application of Silk Nanoparticles","authors":"Saphia A. L. Matthew, F. Philipp Seib","doi":"10.1002/adtp.202400130","DOIUrl":"https://doi.org/10.1002/adtp.202400130","url":null,"abstract":"This review introduces nanomedicines and medical silks by addressing seminal and recent research within these fields. First, the successes of nanoparticles in improving the safety profiles and pharmacokinetic–pharmacodynamic properties are explored but also the concepts of threshold dosing and targeting of tumor-associated macrophages. Current barriers to systemic delivery of nanomedicines are detailed and methods to overcome these barriers and increase tumor targeting are evaluated, namely: tuning the nanomedicine size and surface charge for enhanced tumor accumulation and penetration; non-spherical nanomedicine morphologies for macrophage evasion and targeted delivery to endothelial cells; and, surface functionalization for stealth coatings and targeting receptor-mediated endocytosis. The advantages of using silk as a nanomedicine with reference to its structure, composition, biological performance, and formulation are discussed. While batch methods for silk processing enable the formation of nano to microparticles, continuous technology can overcome bottlenecks of the deployed engineering methods such as low throughput and poor reproducibility. Finally, the chemical modification of silk using homogeneous and heterogenous chemistries is assessed within the nanomedicine context. Overall, this review covers silk nanomedicines from first principles to carrier design and on to areas of future development.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400130","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143121233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cocktail Polyplexes With Synchronous Flightless I siRNA and Nitric Oxide Release for Potential Chronic Wound Healing 具有同步无飞行siRNA和一氧化氮释放的鸡尾酒复合物用于潜在的慢性伤口愈合

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-23 DOI: 10.1002/adtp.202400329

Mahshid Kharaziha, Sahar Salehi, Thomas Scheibel

{"title":"Cocktail Polyplexes With Synchronous Flightless I siRNA and Nitric Oxide Release for Potential Chronic Wound Healing","authors":"Mahshid Kharaziha, Sahar Salehi, Thomas Scheibel","doi":"10.1002/adtp.202400329","DOIUrl":"https://doi.org/10.1002/adtp.202400329","url":null,"abstract":"Chronic wounds are one of the health challenges threatening human life. In these wounds, overexpression of some types of cytoskeletal actin-remodeling proteins including Flightless I (Flii) can often lead to severe skin scarring. Herein, arginine functionalized poly(β-amino ester)s are synthesized to develop polyplexes with alginate for delivery of Flii siRNA. This approach results in forming polyplexes with distinct features, such as tunable zeta potential, particle size, polydispersity, and arginine conjugation level. It is demonstrated that the uptake of arginine functionalized poly(β-amino ester)/alginate particles is composition-dependent for various cell types including J774.1 macrophages and BJ fibroblasts. Such polyplexes trigger nitric oxide release by macrophages enhancing the expression of anti-inflammatory genes while diminishing the expression of pro-inflammatory markers and demonstrating its immunomodulatory properties. Flii siRNA loaded particles provide condensed siRNA into the core-shell polyplex and exhibit controlled release of Flii siRNA over 24 h. The uptake rate of this polyplex by macrophages and fibroblasts is higher than that of a commercial gene carrier (Lipofectamine 2000), knocking down the in vitro Flii gene expression (1.3-fold). The increased BJ fibroblast proliferation and higher expression of collagen I (COL I) show the suitability of these polyplexes for wound healing.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142868945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ROS-Activatable Prodrug of Doxazolidine as Novel Cancer Therapy Paradigm 多沙唑烷ros活化前药作为新的癌症治疗范式

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-22 DOI: 10.1002/adtp.202400340

Ryo Tamura, Chace I. Carpenter, Charlotte M. Thomas, Ghazal Kamyabi, Hsiao-Ting Hsu, Olivia Vergnolle, Paul Balderes, Jan Grimm

{"title":"ROS-Activatable Prodrug of Doxazolidine as Novel Cancer Therapy Paradigm","authors":"Ryo Tamura, Chace I. Carpenter, Charlotte M. Thomas, Ghazal Kamyabi, Hsiao-Ting Hsu, Olivia Vergnolle, Paul Balderes, Jan Grimm","doi":"10.1002/adtp.202400340","DOIUrl":"https://doi.org/10.1002/adtp.202400340","url":null,"abstract":"Overcoming severe side effects from anticancer agents without decreasing their effects on tumor growth is a major challenge. A prodrug technology is reported using agents that are spatiotemporally activated primarily in tumors while the extratumoral toxicity to healthy cells is minimized. A ROS-activatable prodrug of a strong anticancer agent, doxazolidine (doxaz), is developed. Doxaz is a DNA alkylating agent with a half-life of 3 min and significantly higher cytotoxicity than the clinically used parental compound doxorubicin (dox). Importantly, doxaz is not affected by p-glycoprotein expression since it irreversibly alkylates DNA while dox inhibits the topoisomerase II DNA complex. As drug activators, reactive oxygen species (ROS) are already produced inside cancer cells in higher abundance than in normal cells but additionally generated by external stimuli such as radionuclides (via radiolysis of water) and/or ROS-inducing drugs. We synthesized the prodrug, Doxaz-BA, and evaluated its efficacy in vitro in cell cultures and then in vivo in xenograft mouse models. Doxaz-BA is effective in a broad range of cancer cells since most cancer cells produce higher levels of ROS. Combining with clinically relevant radiotracers such as 18F-FDG or other tumor-tropic agents / ROS inducing drugs results in a tumor-specific and enhanced localized therapy paradigm.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142868889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Overview of the Cancer Targeting Attributes of the Elastin Like Polypeptide Nano-Carriers: Discerning Active and Passive Modes 弹性蛋白样多肽纳米载体的癌症靶向特性综述：区分主动和被动模式

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-22 DOI: 10.1002/adtp.202400332

Ridhima Goel, Deepak Gulwani, Priyanka Upadhyay, Vijaya Sarangthem, Thoudam Debraj Singh

{"title":"An Overview of the Cancer Targeting Attributes of the Elastin Like Polypeptide Nano-Carriers: Discerning Active and Passive Modes","authors":"Ridhima Goel, Deepak Gulwani, Priyanka Upadhyay, Vijaya Sarangthem, Thoudam Debraj Singh","doi":"10.1002/adtp.202400332","DOIUrl":"https://doi.org/10.1002/adtp.202400332","url":null,"abstract":"Since the 1940s, generalized cytotoxic therapy has been a valuable tool in cancer treatment. Over the years, there's been a significant increase in developing potential cytotoxic drugs. However, little progress has been made in enhancing patients' quality of life. The therapeutic index is limited due to the drug's poor solubility and lack of selectivity. Various carriers have been explored for drug delivery to enhance efficacy. Yet, there's a gap for a versatile delivery system that can adjust to specific drug and application requirements. Here, a multifaceted drug delivery platform based on a genetically engineered nature-inspired polymer, elastin-like polypeptide (ELP) is introduced. This technology enables the customization of the polymeric vehicle's physicochemical characteristics to suit the needs of a specific drug and application. The review highlights ELP's advantages in cancer targeting, such as site-specificity, controlled release, biocompatibility, and extended plasma circulation. For the first time, ELP-based drug delivery into passive and active targeting for better comprehension of its adaptability is classified. Moreover, numerous opportunities for loading different types of drugs onto the polymer are outlined. Finally, the polymer's efficacy in delivery across multiple cancer types, underscoring the wide spectrum of ELP-based cancer drug delivery is precisely described.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142868890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Albumin-Loaded Silica Nanomaterials Functionalized with Organotin(IV) Agents: Theranostic Materials Against Triple-Negative Breast Cancer (Adv. Therap. 10/2024) 用有机锡（IV）制剂功能化的白蛋白负载二氧化硅纳米材料：针对三阴性乳腺癌的治疗材料（Adv.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-13 DOI: 10.1002/adtp.202470021

Victoria García-Almodóvar, Karina Ovejero-Paredes, Diana Díaz-García, José M. Méndez-Arriaga, Sanjiv Prashar, Marco Filice, Santiago Gómez-Ruiz

引用次数: 0

Urine Liquid Biopsies via Highly Integrated Digital PCR System for Accurate Detection of Bladder Cancer (Adv. Therap. 10/2024) 通过高度集成的数字 PCR 系统进行尿液液体活检以准确检测膀胱癌（Adv. Therap.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-13 DOI: 10.1002/adtp.202470020

Yue Zhang, Ming Xu, Zhihong Wu, Fan Yang, Lu Zhang, Yiquan Liu, Jiahao Lv, Shuyue Xiang, Beiyuan Fan, Zijian Zhao, Yanzhao Li, Yang Yu

引用次数: 0

Issue Information (Adv. Therap. 10/2024) 发行信息（Adv. Therap.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-13 DOI: 10.1002/adtp.202470022

引用次数: 0

In Vivo Combined Photoacoustic Imaging and Photothermal Treatment of HPV-Negative Head and Neck Carcinoma with NIR-Responsive Non-Persistent Plasmon Nano-Architectures (Adv. Therap. 10/2024) 利用近红外响应性非持久性等离子体纳米结构对HPV阴性头颈癌进行体内光声成像和光热治疗（Adv.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-13 DOI: 10.1002/adtp.202470023

Valentina Frusca, Chiara Cavallini, Agata Zamborlin, Giuliana Drava, Virginia Barone, Lisa Gherardini, Mario Chiariello, Paolo Armanetti, Maria Laura Ermini, Luca Menichetti, Valerio Voliani

引用次数: 0

Unlocking the Potential of Chemically Modified Nucleic Acid Therapeutics 释放化学修饰核酸疗法的潜力

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-11 DOI: 10.1002/adtp.202400231

Jingjing Gao, Bhingaradiya Nutan, Dorra Gargouri, Nishkal D. Pisal, Vy Do, Muhammad Zubair, Hommam Alanzi, Hiqui Wang, Dongtak Lee, Nitin Joshi, Aman Ullah

{"title":"Unlocking the Potential of Chemically Modified Nucleic Acid Therapeutics","authors":"Jingjing Gao, Bhingaradiya Nutan, Dorra Gargouri, Nishkal D. Pisal, Vy Do, Muhammad Zubair, Hommam Alanzi, Hiqui Wang, Dongtak Lee, Nitin Joshi, Aman Ullah","doi":"10.1002/adtp.202400231","DOIUrl":"https://doi.org/10.1002/adtp.202400231","url":null,"abstract":"Nucleic acid therapeutics have demonstrated tremendous potential for treating diseases by targeting the genetic underpinnings at the transcriptomic level. However, their efficacy hinges on robust strategies to protect nucleic acids from degradation during circulation and to facilitate precise delivery to diseased tissues and cells. Here the critical roles of chemical modification and bioconjugation in advancing nucleic acid therapeutics for improved binding affinity, enhanced stability, and targeted delivery are reviewed. Commencing diverse applications, the significance of different chemical modifications is discussed based on recent literature and clinical products, on oligonucleotides. These modifications encompass backbone, ribose, base alterations and bioconjugation techniques such as N-acetylgalactosamine (GAlNac), aptamers, antibodies, and cell-penetrating peptides (CPPs). Supported by a clinical perspective, diverse applications and ongoing developments are highlighted. Furthermore, the current landscape of nucleic acid therapeutics and their potential in addressing genetic disorders with multiple cellular/organelle targeting is discussed. Here the promising prospect of combining chemical innovation and bioconjugation strategies is underscored to propel the development of more effective nucleic acid therapeutics.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400231","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0